Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ctDNA-MRD and Imaging Response-Guided Adaptive Escalation of Neoadjuvant Therapy in NSCLC
NCT07885709Phase 2Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Nov 2026
- Primary completion
- Jan 2029
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in non-small cell lung cancer (NSCLC), sponsored by Peking University People's Hospital. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07885709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07885709.